| GUFIC BIOSCIENCES  Back to All Ratios | 
GUFIC BIOSCIENCES Last 5 Year Sales/Fixed Asset History
[Consolidated]
| Mar2025 | Mar2024 | |
|---|---|---|
| Sales/Fixed Asset(x) | 2.56 | 3.82 | 
What is the latest Sales/Fixed Asset ratio of GUFIC BIOSCIENCES ?
| Year | Sales/Fixed Asset | 
|---|---|
| Mar2025 | 2.56 | 
| Mar2024 | 3.82 | 
How is Sales/Fixed Asset of GUFIC BIOSCIENCES Trending?
| Years | Sales/Fixed Asset | % Change | |
|---|---|---|---|
| Mar2025 | 2.56 | -32.98 | |
| Mar2024 | 3.82 | - | |
Other Financial Ratios of GUFIC BIOSCIENCES
| Operational & Financial Ratios Earnings Per Share CEPS DPS Book NAV/Share Tax Rate | Margin Ratios Core EBITDA Margin EBIT Margin Pre Tax Margin PAT Margin Cash Profit Margin | Performance Ratios ROA ROE ROCE Asset Turnover Working Capital/Sales | Efficiency Ratios Fixed Capital/Sales Receivable days Inventory Days Payable days | Valuation Parameters PER PCE Price/Book Yield EV/Net Sales EV/Core EBITDA EV/EBIT EV/CE M Cap / Sales | Growth Ratios Net Sales Growth Core EBITDA Growth EBIT Growth PAT Growth EPS Growth | Financial Stability Ratios Total Debt/Equity Current Ratio Quick Ratio Interest Cover Total Debt/Mcap | 
Compare Sales/Fixed Asset ratio of peers of GUFIC BIOSCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUFIC BIOSCIENCES | ₹3,422.7 Cr | -3% | -8.2% | -23.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹407,791.0 Cr | 1.2% | 4.2% | -10.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,885.0 Cr | -0.5% | 8.9% | 10.8% | Stock Analytics | |
| CIPLA | ₹127,930.0 Cr | 0.4% | 3.7% | 8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹121,108.0 Cr | -0% | -2.1% | 6.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,164.0 Cr | 2.2% | -1.8% | -4.4% | Stock Analytics | |
GUFIC BIOSCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year | 
| GUFIC BIOSCIENCES | -3% | -8.2% | -23.3% | 
| SENSEX | 0.9% | 2.5% | 3.7% | 
You may also like the below Video Courses
 
                     
                                     
                                     
                                    